Karim Fizazi
Institut Gustave Roussy
770 Papers
3.2K Citations
Karim Fizazi is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 96, co-authored 658 publications. Previous affiliations of Karim Fizazi include Université Paris-Saclay & University College London.
Chat about Author
Papers
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
618
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Martin Bambury,Eric Voog,Jingsong Zhang,Josep M. Piulats,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Celestia S. Higano,Laurence Eliot Miles Krieger,Cora N. Sternberg,Simon Paul Watkins,Darrin Despain,Andrew Simmons,Andrea Loehr,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury,Simon Chowdhury +27 more
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
605
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Bertrand Tombal,Christian Wülfing,Gero Kramer,Jean-Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Theodore,Susan Feyerabend,Carole Helissey,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Daniel Castellano,Card Investigators +19 more
TL;DR: Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen
581
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun +18 more
TL;DR: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
556
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Susan Halabi,Chen-Yen Lin,W. Kevin Kelly,Karim Fizazi,Judd W. Moul,Ellen B. Kaplan,Michael J. Morris,Eric J. Small +7 more
TL;DR: An updated prognostic model for OS in patients with mCRPC receiving first-line chemotherapy was developed and validated on an external set and can be used to predict OS, as well as to better select patients to participate in trials on the basis of their prognosis.